Boehringer Ingelheim

2:00 PM - 2:15 PM, Wednesday, June 5, 2019 ・ Theater 1
Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention. Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.
Ticker:
Not Provided.
Exchange:
Not Provided.
Company Type:
Company Website:
Company HQ State:
Not Provided.
Company HQ Country:
Germany
Year Founded:
1885
Main Therapeutic Focus:
Lead Product in Development:
NA
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided.
Speaker
photo
Corporate Sr. Vice President, Bus. Dev. & Licensing
Boehringer Ingelheim Pharmaceuticals, Inc .